[1]
Q. Zhang, “Pharmacoeconomic Evaluation of an Olanzapine-Containing Quadruple Antiemetic Regimen for the Prevention of CINV: An Efficacy-Cost Analysis”, ESS, vol. 12, pp. 98–103, Feb. 2026, doi: 10.70267/lshe.20260112.